Toronto Dominion Bank lifted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 33.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,858 shares of the specialty pharmaceutical company’s stock after buying an additional 2,725 shares during the quarter. Toronto Dominion Bank’s holdings in Jazz Pharmaceuticals were worth $1,552,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of JAZZ. Mn Services Vermogensbeheer B.V. boosted its position in Jazz Pharmaceuticals by 0.9% during the first quarter. Mn Services Vermogensbeheer B.V. now owns 32,944 shares of the specialty pharmaceutical company’s stock worth $4,709,000 after purchasing an additional 300 shares in the last quarter. First Allied Advisory Services Inc. raised its holdings in shares of Jazz Pharmaceuticals by 17.1% during the first quarter. First Allied Advisory Services Inc. now owns 3,562 shares of the specialty pharmaceutical company’s stock valued at $510,000 after acquiring an additional 520 shares during the last quarter. OLD National Bancorp IN acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $218,000. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Jazz Pharmaceuticals by 3.7% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,534 shares of the specialty pharmaceutical company’s stock valued at $791,000 after acquiring an additional 196 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of Jazz Pharmaceuticals by 4.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 73,439 shares of the specialty pharmaceutical company’s stock valued at $10,498,000 after acquiring an additional 2,974 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.
Shares of NASDAQ:JAZZ traded down $0.66 during midday trading on Friday, hitting $136.76. The company had a trading volume of 544,443 shares, compared to its average volume of 625,601. Jazz Pharmaceuticals PLC has a twelve month low of $113.52 and a twelve month high of $184.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.01 and a current ratio of 3.15. The stock has a market cap of $7.75 billion, a PE ratio of 11.17, a P/E/G ratio of 1.11 and a beta of 1.16.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating the consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a return on equity of 27.35% and a net margin of 24.88%. The firm had revenue of $508.19 million during the quarter, compared to analysts’ expectations of $466.55 million. During the same quarter last year, the firm earned $2.98 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 13.24 earnings per share for the current fiscal year.
A number of brokerages have commented on JAZZ. ValuEngine raised Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 8th. HC Wainwright reissued a “hold” rating and set a $153.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, May 10th. Zacks Investment Research raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a report on Tuesday, April 16th. Mizuho increased their target price on Jazz Pharmaceuticals from $146.00 to $148.00 and gave the company a “neutral” rating in a report on Wednesday, May 8th. Finally, BMO Capital Markets increased their target price on Jazz Pharmaceuticals from $206.00 to $208.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the stock. Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $182.41.
In other Jazz Pharmaceuticals news, EVP Suzanne Sawochka Hooper sold 6,666 shares of the firm’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total transaction of $933,240.00. Following the completion of the sale, the executive vice president now owns 40,401 shares of the company’s stock, valued at $5,656,140. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Matthew P. Young sold 1,916 shares of the firm’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $131.46, for a total value of $251,877.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,668 shares of company stock valued at $1,606,567. Insiders own 3.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was reported by Zolmax and is the sole property of of Zolmax. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://zolmax.com/investing/toronto-dominion-bank-buys-2725-shares-of-jazz-pharmaceuticals-plc-jazz/3095166.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: How Do Mutual Funds Work?
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.